2-((2-bromoethyl)-2-{[(2-hydroxypropyl)amino]carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate | 680199-08-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((2-bromoethyl)-2-{[(2-hydroxypropyl)amino]carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate
• 英文别名: 2-((2-Bromoethyl)-2-([(2-hydroxypropyl)amino]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate；2-[N-(2-bromoethyl)-2-(2-hydroxypropylcarbamoyl)-4,6-dinitroanilino]ethyl methanesulfonate
• CAS: 680199-08-0
• 化学式: C₁₅H₂₁BrN₄O₉S
• 分子量: 513.323
• InChiKey: KQNJLOZYSLLLQE-UHFFFAOYSA-N

物化性质

• 沸点：
  682.7±55.0 °C(Predicted)
• 密度：
  1.642±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  196
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-(2-{[(3-hydroxypropyl)amino]carbonyl}{2-[(methylsulfonyl)oxy]ethyl}-4,6-dinitroanilino)ethyl methanesulfonate 在 lithium bromide 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 以66%的产率得到2-((2-bromoethyl)-2-{[(2-hydroxypropyl)amino]carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate
  参考文献：
  名称：

  [EN] NOVEL NITROPHENYL MUSTARD AND NITROPHENYLAZIRIDINE ALCOHOLS AND THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS
  [FR] NOUVELLE MOUTARDE NITROPHENYLE ET NOUVEAUX ALCOOLS NITROPHENYLAZIRIDINE, PHOSPHATES CORRESPONDANTS ET UTILISATION DE CES DERNIERS EN TANT QU'AGENTS CYTOTOXIQUES CIBLES

  摘要：

  本发明涉及新型硝基苯基芥和硝基苯基环丙胺醇，它们的相应磷酸盐，以及它们作为靶向细胞毒性药剂的用途；作为缺氧肿瘤中的生物还原药物，并且它们在细胞消融中的应用，包括基因导向酶前药治疗（GDEPT）和抗体导向酶前药治疗（ADEPT），与硝基还原酶酶一起。

  公开号：

  WO2005042471A1

文献信息

• [EN] NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS<br/>[FR] AGENTS D'ALKYLATION A BASE DE NITROANILINE ET LEUR UTILISATION EN TANT QUE PROMEDICAMENTS
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2004033415A1

  公开（公告）日：2004-04-22

  Nitroaniline-based unsymmetrical mustards of the general formula (I) are provided, together with methods of preparation and methods for their use as produgs for gene-dependent enzyme prodrug therapy (GDEPT) and cell ablation therapy in conjuction with nitroreductase enzymes as hypoxia selective cytotoxins and as anticancer agents.

  基于硝基苯胺的不对称芥末化合物，其通用公式为（I），以及它们的制备方法和使用方法，作为基因依赖性酶前药治疗（GDEPT）和与硝基还原酶酶结合的细胞消融治疗的药物，以及作为缺氧选择性细胞毒素和抗癌药物的使用方法。
• Nitroaniline-based alkylating agents and their use as prodrugs
  申请人：Denny Alexander William

  公开号：US20050256191A1

  公开（公告）日：2005-11-17

  Nitroaniline-based unsymmetrical mustards of the general formula (I) are provided, together with methods of preparation and methods for their use as prodrugs for gene-dependent enzyme prodrug therapy (GDEPT) and cell ablation therapy in conjunction with nitroreductase enzymes as hypoxia selective cytotoxins and as anticancer agents.

  提供了基于硝基苯胺的不对称芥子气的一般式（I），以及其制备方法和用作基因依赖性酶前药治疗（GDEPT）和细胞消融治疗的前药的方法，与硝酸还原酶酶一起使用作为缺氧选择性细胞毒素和抗癌剂。
• Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
  申请人：Denny William Alexander

  公开号：US20100010094A1

  公开（公告）日：2010-01-14

  The present invention relates to novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumours, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT), in conjunction with nitroreductase enzymes.

  本发明涉及新型的硝基苯基芥和硝基苯基环氧丙烷醇，它们对应的磷酸盐，以及它们作为靶向细胞毒性药物的使用；作为缺氧肿瘤中的生物还原药物，并结合硝酸还原酶酶使用于细胞消融，包括基因定向酶前药物治疗（GDEPT）和抗体定向酶前药物治疗（ADEPT）。
• Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
  申请人：Auckland Uniservices Limited

  公开号：US07629332B2

  公开（公告）日：2009-12-08

  The present invention relates to a novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumors, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GPEPT) and antibody-directed enzymeprodrug therapy (ADEPT), in conjunction with nitroreductase enzymes.

  本发明涉及一种新型的硝基苯基芥和硝基苯基环丙烷醇，以及它们对应的磷酸酯，它们作为靶向细胞毒性药物的用途；作为低氧肿瘤中的生物还原药物，并结合硝酸还原酶酶使用于细胞消融，包括基因定向酶前药治疗（GPEPT）和抗体定向酶前药治疗（ADEPT）。
• NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS
  申请人：Auckland Uniservices Limited

  公开号：EP1558568A1

  公开（公告）日：2005-08-03